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One-Hour Plasma Glucose Identifies Insulin
Resistance and -Cell Dysfunction in
Individuals With Normal Glucose Tolerance
Cross-sectional data from the Relationship between Insulin Sensitivity and
Cardiovascular Risk (RISC) study
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INSULIN SENSITIVITY AND
CARDIOVASCULAR RISK (RISC)
CONSORTIUM
OBJECTIVE— Some individuals with normal glucose tolerance (NGT) exhibit a 1-h excur-
sion of plasma glucose during oral glucose tolerance testing as high as that of individuals with
impaired glucose tolerance (IGT). The aim of this study was to characterize their metabolic
phenotype.
RESEARCH DESIGN AND METHODS— A total of 1,205 healthy volunteers (aged
29–61 years) underwent assessment of 1) oral glucose tolerance and 2) insulin sensitivity
(standardized euglycemic-hyperinsulinemic clamp), as part of the Relationship between Insulin
Sensitivity and Cardiovascular Risk (RISC) study.
RESULTS— One-hour plasma glucose correlated better than 2-h plasma glucose with
total insulin secretion (r  0.43), -cell glucose sensitivity (r  0.46), and -cell rate
sensitivity (r  0.18). Receiver operating characteristic analysis identified 8.95 mmol/l as
the best cutoff value for prediction of IGT from 1-h plasma glucose (sensitivity 77% and
specificity 80%). Participants with NGT with 1-h plasma glucose 8.95 mmol/l had larger
waist circumference, higher BMI, lower insulin sensitivity, higher fasting glucose, and
higher insulin secretion than their counterparts with 1-h plasma glucose8.95 mmol/l (P
0.001 for all comparisons). Moreover, they exhibited lower -cell glucose sensitivity (P 
0.001), -cell rate sensitivity (P  0.001), and potentiation factor (P  0.026). When
compared with conventionally defined IGT, they were not different in waist circumference
and BMI, hepatic insulin extraction, -cell glucose sensitivity, -cell rate sensitivity, and
potentiation factor but did have greater insulin sensitivity along with reduced basal (P 
0.001) and total insulin secretion (P  0.002).
CONCLUSIONS— Higher values of 1-h plasma glucose may identify an intermediate con-
dition between NGT and IGT characterized by greater insulin resistance, reduced -cell glucose
sensitivity, and reduced -cell rate sensitivity.
Diabetes Care 33:2090–2097, 2010
Impaired glucose tolerance (IGT) andimpaired fasting glucose (IFG) arestates of carbohydrate metabolism in-
termediate between normal glucose toler-
ance (NGT) and type 2 diabetes, which
represent two partially overlapping con-
ditions with distinct metabolic charac-
teristics (1,2). In IFG, there is marked
hepatic insulin resistance with near-
normal muscle insulin sensitivity,
whereas this pattern is reversed in IGT
(2). Although both conditions are charac-
terized by reduced early-phase insulin se-
cretion, there is an additional impairment
of late-phase insulin secretion in IGT. Ac-
cordingly, individuals with IGT have a
rapid early (30 min) rise in plasma glu-
cose during an oral glucose tolerance test
(OGTT) which continues to rise until 60
min (1-h plasma glucose) and thereafter
remains7.8 mmol/l (140 mg/dl) at 120
min (2-h plasma glucose).
As longitudinal studies have demon-
strated that 40% of patients who develop
type 2 diabetes after 10 years have NGT at
baseline (1), there may be additional in-
formation beyond conventional IFG/IGT
categories that may better discriminate fu-
ture progression to type 2 diabetes (3).
We have noted a subset of individuals
with NGT who have early glucose excur-
sions during an OGTT as high as those
observed in individuals with IGT. How-
ever, because plasma glucose concentra-
tions decline adequately by 2 h, due to
preservation of late-phase insulin secre-
tion, these individuals do not have, by
current definitions, any form of disor-
dered carbohydrate metabolism (4). Data
from the San Antonio Study have shown
that -cell glucose sensitivity and insulin
sensitivity contribute to values of 2-h
plasma glucose independently of each
other (5); thus, we hypothesized that in-
dividuals with NGT with 1-h plasma glu-
cose levels as high as in those with IGT
might represent an intermediate pheno-
type of abnormal carbohydrate metabo-
lism with either impaired insulin
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sensitivity or -cell glucose sensitivity,
who are potentially at increased risk of
progression to type 2 diabetes.
To investigate this hypothesis we an-
alyzed cross-sectional data from the Eu-
ropean Relationship between Insulin
Sensitivity and Cardiovascular Risk
(RISC) study (6), examining the meta-
bolic phenotype of individuals with NGT
who had high 1-h plasma glucose excur-
sions. We aimed to identify a new glucose
tolerance subgroup who might benefit
from targeted lifestyle advice and/or phar-
macological intervention.
RESEARCH DESIGN AND
METHODS— The RISC study is a pro-
spective (3- and 10-year follow-up), obser-
vational, cohort study. Primary objectives
include 1) establishing whether insulin re-
sistance predicts deterioration of cardiovas-
cular risk markers, diabetes, obesity,
atherosclerosis, and cardiovascular disease
and 2) developing methods based on math-
ematical modeling to identify insulin-
resistant participants in clinical practice.
Healthy adults, aged 29–61, with no
history of diabetes, hypertension, or hy-
perlipidemia were recruited from 18 cen-
ters across Europe between 2002 and
2004. Specific inclusion and exclusion
criteria are reported elsewhere (6). Partic-
ipants gave written informed consent and
local ethics committee approval was ob-
tained in each center. Every volunteer had
a clinical examination, including body
composition estimated by bioimpedance
(TBF-300 body composition analyzer;
Tanita, Hoofddorp, the Netherlands), and
underwent a 75-g OGTT and euglycemic-
hyperinsulinemic clamp (EHC).
OGTT
After an overnight fast, a 75-g OGTT was
performed in the morning, with sampling
at baseline and at 30, 60, 90, and 120 min
after glucose ingestion, with measure-
ment of glucose, insulin, and C-peptide.
Data from the OGTT were used for assess-
ment of -cell function and calculation of
mean hepat ic insul in extrac t ion
[(HIEOGTT  1  (clearance from the
clamp)/(endogenous clearance during the
OGTT)].
EHC
One to 3 weeks after the OGTT, an EHC
was performed in all participants. Exoge-
nous insulin was administered as primed-
continuous infusion at a rate of 240 pmol 
min1  m2, with a simultaneous vari-
able infusion of 20% dextrose adjusted
every 5 min to maintain plasma glucose
within 0.8 mmol/l (15%) of the target
glucose level (4.5–5.5 mmol/l). The
clamp procedure was standardized across
centers (6). An initial fasting blood sam-
ple and two samples during the last 40
min of the clamp were taken for measure-
ment of glucose, insulin, and C-peptide
concentrations. Insulin sensitivity was as-
sessed as the mean glucose infusion rate
over the last 40 min of the clamp, cor-
rected for mean plasma insulin levels
achieved during the same period (M/I, in
micromoles per minute  per kilogram of
free fat mass [FFM] per nanomoles per
liter). The peripheral clearance of insulin
during the clamp (liters per minute per
meter squared) was computed as follows:
Iclclamp  (240 pmol  min
1  m2 insu-
lin infusion)/(steady-state insulin).
Assessment of -cell function
-Cell function was assessed from the
OGTT using a well-validated model that
describes the relationship between insu-
lin secretion and glucose concentration
(7,8). The model expresses insulin secre-
tion (in picomoles per minute per meter)
as the sum of two components. The first is
-cell glucose sensitivity, which repre-
sents the dependence of insulin secretion
on absolute glucose concentration at any
time point during the OGTT through a
dose-response function relating the two
variables (expressed as the mean slope of
dose response over the observed glucose
range). This dose response is modulated
by a potentiation factor, which accounts
for higher insulin secretion on the de-
scending phase of OGTT hyperglycemia
than at the same glucose concentration on
the ascending phase. The potentiation
factor is a positive function of time and is
constrained to average unity during the
experiment (9). The second insulin secre-
tion component represents the depen-
dence of insulin secretion on the rate of
change of glucose concentration. This
component is determined by a single pa-
rameter, denoted as rate sensitivity, and is
related to early insulin release (9).
The model parameters were esti-
mated from glucose and C-peptide con-
centrations by regularized least squares
(7,8). Insulin secretion rates were calcu-
lated from the model every 5 min. The
integral of insulin secretion during the
2-h OGTT was denoted as total insulin
output.
Analytical methods
Local laboratory data were used for study
inclusion criteria. Blood collected was
stored at20°C and centrally analyzed in
Odense, Denmark. Plasma glucose was
measured by the glucose oxidase tech-
nique (Cobas Integra; Roche, Basel, Swit-
zerland); serum insulin and C-peptide
were measured by a specific time-
resolved fluoroimmunoassay (Au-
toDELFIA insulin kit; Wallac Oy, Turku,
Finland).
Statistical analysis
Continuous data are reported as mean 
SD, with categorical data as counts and
percentages. 2 tests was used for com-
paring association between categorical
variables, and ANOVA was performed for
comparison among groups and for re-
peated measures. Stepwise logistic regres-
sion analysis was used to predict insulin
resistance from age, sex, 1-h plasma glu-
cose, 2-h plasma glucose, BMI, and waist
circumference. Receiver operating char-
acteristic curve analysis was used to eval-
uate specificity and sensitivity of plasma
glucose at 60 min to identify individuals
with IGT. Odds ratios (ORs) were com-
puted to estimate risk of insulin resistance
or impaired insulin secretion according to
1-h plasma glucose levels.
Insulin sensitivity was expressed as
the natural logarithm of the M/I ratio. In-
sulin resistance was defined categorically
as the lowest decile of the ln(M/I) as done
previously (10) in those participants who
were nonobese (BMI 25 kg/m2), with
normal values of fasting and 2-h glucose
and no family history for diabetes. Indi-
viduals satisfying these criteria served as
the control subjects. Categories of “insu-
lin hypersecretion” and “insulin hypose-
cretion” were defined as the upper and the
lowest deciles of insulin secretion (basal
or total), in those control subjects pre-
senting with insulin sensitivity between
the lowest and the upper deciles of
ln(M/I). The same approach (upper and
lower deciles) was also used for hepatic
insulin extraction, peripheral insulin
clearance, -cell glucose sensitivity, and
rate sensitivity. IFG and IGT were defined
according to the criteria of the American
Diabetes Association (4).
P  0.05 was considered as statisti-
cally significant. Data analysis was per-
formed with SPSS statistical software
(version 12.0; SPSS, Chicago, IL).
RESULTS— After we excluded indi-
viduals from the initial sample (n 
Manco and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 2091
1,566) with IFG (n  72), with type 2
diabetes (n 30), or with missing OGTT
and clamp data (n 309), 1,205 (56.1%
women) individuals (aged 44  8 years)
with complete EHC data were included in
the analysis. Of these, 509 participants
(42.2%) were overweight or obese (BMI
25 kg/m2) and 105 met the criteria for
IGT (8.7%).
Prevalence of insulin resistance
Thirty-two overweight/obese participants
(mean BMI 28.45  3.04 kg/m2) were
insulin resistant [ln(M/I) 4.48). Among
these insulin-resistant individuals, 41%
had total cholesterol 5.2 mmol/l (P 
0.001, in comparison with insulin-
sensitive individuals), 42% had LDL cho-
lesterol 3.3 mmol/l (P  0.002), 37%
had HDL cholesterol 1.03 mmol/l
(men) or 1.3 (women) (P  0.001),
24% had circulating triglycerides 1.7
mmol/l (P 0.001), and 42% had a waist
circumference 102 cm (men) or 88
cm (women) (P  0.001).
Prevalence of insulin hyper- and
hyposecretion
There were 341 (28.3%) “hypersecretors”
and 80 (6.6%) “hyposecretors,” defined
as 86.42 and 38.13 pmol  min1 
m2, respectively (equivalent figures
were 43.12 and 3.05%, respectively, for
overweight/obese participants). For total
insulin secretion, there were 230 (19.1%)
hypersecretors and 110 (9.1%) hypose-
cretors, defined as 51.97 and 25.21
nmol  m2 (equivalent figures were 26.1
and 7 .1% for ove rwe igh t /obese
participants).
Insulin resistance, 1-h plasma
glucose, and 2-h plasma glucose
Both 1-h plasma glucose and 2-h plasma
glucose values were inversely related to
insulin sensitivity (1-h plasma glucose
6.74 1.9 mmol/l in insulin-sensitive in-
dividuals, 7.3  2.1 mmol/l in subjects
with intermediate insulin sensitivity, and
8.6 2.1 mmol/l in insulin-resistant sub-
jects, P  0.001; 2-h plasma glucose
5.0  1.2, 5.5  1.3, and 6.4  1.5
mmol/l, respectively, P  0.001). Glu-
cose concentrations of insulin-resistant
participants during the OGTT were
higher than those of other participants at
all time points (P  0.0001, repeated-
measures ANOVA, time points, group,
and time per group), the greatest differ-
ence being at 1 h (7.2 2.1 vs. 8.6 2.1
mmol/l, corresponding to a difference of
25 mg/dl). In contrast, 2-h plasma glu-
cose values were 5.5  1.3 vs. 6.4  1.5
mmol/l (a difference of 17 mg/dl).
Insulin sensitivity, hepatic insulin ex-
traction, basal and total insulin secretion,
-cell glucose sensitivity, rate sensitivity,
and potentiation factor correlated signifi-
cantly with both 1-h plasma glucose and
2-h plasma glucose (supplementary Table
1S, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-2261/DC1), although
higher r values were noted for 1-h plasma
glucose than for 2-h plasma glucose in
the correlations with total insulin secre-
tion, -cell glucose sensitivity, and rate
sensitivity.
Independent and significant predic-
tors of insulin resistance determined by
stepwise logistic regression, using the
variables of sex, age, 1-h plasma glucose,
2-h plasma glucose, BMI, and waist cir-
cumference, were 1-h plasma glucose
(OR 1.10 [95% CI 1.01–1.20]), 2-h
plasma glucose (1.41 [1.24–1.60]), BMI
(1.23 [1.18–1.29]), and female sex (0.41
[0.29–0.57]).
Insulin secretion, 1-h plasma
glucose, and 2-h plasma glucose
Whether considering total or basal insulin
secretion, we found that hypersecretors
had higher 1-h plasma glucose and 2-h
plasma glucose values (P  0.001 by
ANOVA for all Bonferroni pairwise com-
parisons) (Table 1), although no differ-
ence in 1-h plasma glucose or 2-h plasma
glucose was detected between hyposecre-
tors and participants with normal secre-
tion. No difference in 1-h plasma glucose
or 2-h plasma glucose was detected when
participants were categorized according
to insulin clearance (P 0.09) or hepatic
insulin extraction (P 0.2), respectively.
Insulin resistance and insulin
secretion in participants with NGT
categorized by IGT-based threshold
of 1-h plasma glucose
Mean 1-h plasma glucose in the 105 indi-
viduals with IGT was 10.11  1.67
mmol/l (upper and lower deciles 12.04
and 7.86 mmol/l). Receiver operating
characteristic curve analysis for sensitivity
and specificity of 1-h plasma glucose to
predict IGT provided an area of 0.86 
0.02 (P  0.001) with a glucose level of
8.95 mmol/l (sensitivity 77% and speci-
ficity 80%), maximizing sensitivity and
specificity. When this 1-h plasma glucose
threshold was used to categorize individ-
uals with NGT (Table 2), 222 participants
had 1-h plasma glucose 8.95 mmol/l
and 878 participants with NGT had 1-h
plasma glucose 8.95 mmol/l.
Comparison of participants with
NGT, NGT with 1-h plasma
glucose >8.95 mmol/l, and IGT
ANOVA was significant for all variables
considered except insulin clearance dur-
ing the EHC. Post hoc comparisons of
participants with NGT with 1-h plasma
glucose 8.95 mmol/l demonstrated sig-
nificantly larger waist circumference
(90.6 12.3 vs. 84.3 11.9 cm), higher
BMI (26.2  3.9 vs. 24.9  3.8 kg/m2),
lower ln(M/I) (4.7  0.5 vs. 4.9  0.5,
corresponding to 110 vs. 134 	mol 
min1  kgFFM
1  nmol/l1), higher fast-
ing glucose (5.2  0.5 vs. 4.9  0.5
mmol/l), and higher basal (82.9  31.7
vs. 68.9 27.5 pmol  min1  m2) and
total insulin secretion (47.9  13.9 vs.
37.8 12 nmol  m2) (P 0.001 for all
comparisons) than their counterparts with
NGT with 1-h plasma glucose 8.95
mmol/l (Table 2). Moreover, they exhibited
lower glucose sensitivity (86.9  30.3 vs.
153.1 97.3 pmol  min1  m2  mmol/
l1; P  0.001), lower rate sensitivity
(781.8561.7 vs. 1150.21431.5 pmol 
m2  mmol/l1; P 0.001), lower poten-
tiation factor (1.9 1.0 vs. 2.2 1.6; P
0.026), higher total cholesterol (5.04 
0.9 vs. 4.8  0.9 mmol/l; P  0.001),
lower HDL cholesterol (1.35  0.4 vs.
1.47  0.4 mmol/l; P  0.001), higher
LDL cholesterol (3.1 0.8 vs. 2.8 0.8
mmol/l; P  0.001), and higher triglyc-
erides (1.28  0.9 vs. 1  0.5 mmol/l;
P  0.001) (Fig. 1).
Post hoc comparison of subjects with
NGT and 1-h plasma glucose 8.95
mmol/l versus those with IGT revealed
no difference in age, waist circumfer-
ence, fasting glucose, hepatic insulin
extraction, -cell glucose sensitivity,
rate sensitivity, potentiation factor, to-
tal cholesterol, HDL cholesterol, LDL
cholesterol, and triglycerides. For sub-
jects with IGT, those with NGT with 1-h
plasma glucose8.95 mmol/l had higher
FFM (56.7  11.03 vs. 51.8  11.0 kg;
P 0.001), insulin sensitivity [4.7 0.5
vs. 4.5 0.5 log(	mol  min1  kgFFM
1
 nmol/l1); P 0.001) in the presence of
lower basal (82.9 31.6 vs. 95.5 33.4
pmol  min1  m2; P 0.001) and total
insulin secretion (47.9  13.9 vs. 53 
17.8 nmol  m2; P  0.002) (Fig. 1).
Sixty-eight (30.6%) of 222 partici-
pants with NGT with 1-h plasma glucose
8.95 mmol/l were insulin resistant com-
1-h plasma glucose and insulin metabolism
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pared with 131 (14.9%) of 878 partici-
pants with 1-h plasma glucose 8.95
mmol/l (P  0.001). The OR for insulin
resistance was 2.52 (95% CI% 1.8–3.5).
Moreover, in terms of both basal and total
insulin secretion, a higher percentage of
participants with 1-h plasma glucose
8.95 mmol/l were hypersecretors as de-
fined above: (basal) 95 (42.8%) of 222 vs.
191 (21.75%) of 878 (P 0.001; OR 2.7
[1.8–3.7]); and (total) 82 (36.9%) of 222
vs. 102 (11.62%) of 878 (P 0.001; 4.46
[3.2–6.3]).
CONCLUSIONS— Our analysis of
cross-sectional data from the RISC study
suggests that increased 1-h plasma glu-
cose (8.95 mmol/l) on an OGTT iden-
tifies a subgroup of individuals with
increased insulin resistance and -cell
dysfunction (reduced -cell rate sensitiv-
ity, glucose sensitivity, and potentiation
factor) (Fig. 1) who would otherwise be
classified as having NGT by current defi-
nitions (4).
Not unexpectedly, these differences
in insulin sensitivity may relate to in-
creased visceral and total body fat. Thus,
participants with NGT with 1-h plasma
glucose 8.95 mmol/l do not differ from
individuals with IGT in waist circumfer-
ence, insulin clearance, hepatic insulin
extraction, -cell rate sensitivity, glucose
sensitivity, and potentiation factor. How-
ever, participants with NGT with 1-h
plasma glucose 8.95 mmol/l are more
insulin sensitive than those with IGT al-
beit they present already impaired dy-
namic -cell function.
Individuals with NGT but IGT-level
excursions of plasma glucose at 1-h dur-
ing the glucose challenge may therefore
represent an intermediate state of glucose
intolerance. It is known that insulin sen-
sitivity varies over a six-to sevenfold range
in individuals with NGT (10) as -cell
compensation can preserve NGT. Four
factors influence this dynamic relation-
ship: 1) -cell glucose sensitivity, i.e., the
ability of -cells to respond to changes in
plasma glucose concentration; 2) rate sen-
sitivity, i.e., the ability to respond to
changes in the rate of variations of glucose
concentration; 3) potentiation, which
depends on glucose potentiation per se,
incretin potentiation and neural modula-
tion; and 4) the degree of insulin resis-
tance. In the spectrum from glucose
tolerance to intolerance, -cell glucose
sensitivity progressively decreases,
whereas insulin secretion classically ex-
hibits an inverted U-shape. Rate sensitiv-
ity is impaired in individuals with NGT
with high 1-h plasma glucose to the same
extent as in individuals with IGT.
A higher level of 1-h plasma glucose
might represent a surrogate marker of im-
paired-cell function (-cell glucose sen-
sitivity and rate sensitivity) in individuals
Table 1—One-hour plasma glucose and 2-h plasma glucose after OGTT in subjects stratified according to parameters deriving from the
clamp and from the OGTT
Classification %
1-h plasma
glucose P value
2-h plasma
glucose P value
Insulin clearance (l/min/m2)
Low clearance (0.47) 15.5 7.82  2.22 0.096 5.9  1.41 0.003
Normal clearance (0.470–0.82) 72.9 7.48  2.14 5.67  1.42
High clearance (0.82) 11.6 7.34  2.54 5.37  1.53
Insulin sensitivity 
log(	mol  min1  kgFFM
1  nmol/l1)
Hypersensitivity 
ln(M/I) 5.53 6.4 6.74  1.90 0.001 5.01  1.17 0.001
Normal sensitivity 
4.47  ln(M/I)  5.53 72.9 7.27  2.15 5.51  1.35
Insulin resistance 
ln(M/I) 4.47 20.7 8.63  2.12 6.4  1.51
Total insulin secretion (nmol  m2)
Low secretion (24.60) 9.1 6.15  1.90 0.001 4.87  1.22 0.001
Normal secretion (24.60–54.54) 71.8 7.3  2.05 5.57  1.36
High secretion (54.54) 19.1 8.98  2.20 6.41  1.50
Basal insulin secretion (pmol  min1  m2)
Low secretion (37.98) 6.6 6.78  1.94 0.001 5.18  1.21 0.001
Normal secretion (37.98–92.10) 65.1 7.20  2.04 5.51  1.38
High secretion (92.10) 28.3 8.41  2.37 6.14  1.49
Insulin extraction (adimensional)
Low extraction (0.44) 16.43 8.07  2.46 0.001 5.82  1.54 0.182
Normal extraction (0.44–0.76) 78.09 7.44  2.14 5.65  1.41
High extraction (0.76) 5.48 6.98  2.15 5.49  1.38
Glucose sensitivity (pmol  min1  m2  mmol/l1)
Low sensitivity (54.76) 11.62 8.86  2.89 0.001 6.38  1.74 0.001
Normal sensitivity (54.76–247.37) 80.41 7.54  2.01 5.64  1.38
High sensitivity (247.37) 7.97 5.30  0.99 4.89  0.89
Rate sensitivity (pmol  m2  mmol/l1)
Low sensitivity (3.34  1012) 8.30 6.51  1.91 0.001 5.31  1.28 0.001
Normal sensitivity (3.34  1012–2,494.27) 81.83 7.83  2.18 5.79  1.42
High sensitivity (2,494.27) 9.88 5.75  1.52 4.96  1.39
Data are means  SD or % individuals within each group. P 0.001 from ANOVA. All Bonferroni comparisons were significant except the comparisons between
participants with 1) normal and low basal insulin secretion for both 1-h plasma glucose and 2-h plasma glucose, 2) normal and high hepatic insulin extraction for
1-h plasma glucose, 3) low and high rate sensitivity for 2-h plasma glucose, 4) normal and low as well as normal and high insulin clearance for 2-h plasma glucose,
and 5) normal insulin sensitivity and hypersensitivity for 1-h plasma glucose.
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Table 2—Comparison among participants with NGTwith 1-h plasma glucose<8.95 mmol/l (group 0), participants with NGTwith 1-h plasma
glucose >8.95 mmol/l (group 1), and participants with IGT (group 2)
Classification n Value P value
P value for group comparison
0 vs. 1 1 vs. 2 0 vs. 2
Age (years)
NGT with 1-h plasma glucose 8.95 mmol/l 878 43.01  8.27
NGT with 1-h plasma glucose 8.95 mmol/l 222 45.39  8.26 0.001 0.001 NS 0.001
IGT 105 46.01  7.96
Waist (cm)
NGT with 1-h plasma glucose 8.95 mmol/l 863 84.28  11.88
NGT with 1-h plasma glucose 8.95 mmol/l 220 90.61  12.34 0.001 0.001 NS 0.001
IGT 105 91.38  13.47
BMI (kg/m2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 24.86  3.77
NGT with 1-h plasma glucose 8.95 mmol/l 222 26.25  3.95 0.001 0.001 NS 0.001
IGT 105 27.27  4.39
Insulin sensitivity 
log(	mol  min1  kgFFM
1  nmol/l1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 4.93  0.45
NGT with 1-h plasma glucose 8.95 mmol/l 222 4.73  0.51 0.001 0.001 0.001 0.001
IGT 105 4.49  0.48
Fasting plasma glucose (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 878 4.94  0.49
NGT with 1-h plasma glucose 8.95 mmol/l 222 5.25  0.47 0.001 0.001 NS 0.001
IGT 105 5.17  0.48
Basal insulin secretion (pmol  min1  m2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 68.94  27.52
NGT with 1-h plasma glucose 8.95 mmol/l 222 82.87  31.66 0.001 0.001 0.001 0.001
IGT 105 95.52  33.42
Total insulin secretion (nmol  m2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 37.79  12.00
NGT with 1-h plasma glucose 8.95 mmol/l 222 47.86  13.90 0.001 0.001 0.002 0.001
IGT 105 53.05  17.82
Insulin clearance (l/min/m2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 0.63  0.25
NGT with 1-h plasma glucose 8.95 mmol/l 222 0.62  0.18 NS
IGT 105 0.62  0.23
Insulin extraction
NGT with 1-h plasma glucose 8.95 mmol/l 878 0.59  0.24
NGT with 1-h plasma glucose 8.95 mmol/l 222 0.52  0.48 0.003 NS NS 0.003
IGT 105 0.37  1.90
Glucose sensitivity (pmol  min1  m2  mmol/l1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 153.12  97.34
NGT with 1-h plasma glucose 8.95 mmol/l 222 86.88  30.28 0.001 0.001 NS 0.001
IGT 105 80.38  44.26
Rate sensitivity (pmol  m2  mmol/l1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 1,150.22  1,431.50
NGT with 1-h plasma glucose 8.95 mmol/l 222 781.78  561.72 0.001 0.001 NS NS
IGT 105 987.14  859.81
Potentiation factor
NGT with 1-h plasma glucose 8.95 mmol/l 878 2.17  1.55
NGT with 1-h plasma glucose 8.95 mmol/l 222 1.89  1.04 0.001 0.026 NS 0.001
IGT 105 1.50  0.57
Total cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 874 4.75  0.85
NGT with 1-h plasma glucose 8.95 mmol/l 220 5.04  0.94 0.001 0.001 NS NS
IGT 104 4.92  0.84
(continued)
1-h plasma glucose and insulin metabolism
2094 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.org
otherwise regarded as having NGT who
are insulin resistant. In the RISC cohort,
according to this analysis, NGT partici-
pants with 1-h plasma glucose 8.95
mmol/l had an OR of 2.5 for insulin
resistance.
The concept that hyperglycemia
(even within the normal range of glucose
tolerance) may arise from an intrinsic
-cell defect in the presence of increased
insulin resistance has been reinforced in
recent years by a number of studies in
Table 2—Continued
Classification n Value P value
P value for group comparison
0 vs. 1 1 vs. 2 0 vs. 2
HDL cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 875 1.47  0.38
NGT with 1-h plasma glucose 8.95 mmol/l 220 1.35  0.36 0.001 0.001 NS 0.001
IGT 104 1.33  0.35
LDL cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 870 2.83  0.78
NGT with 1-h plasma glucose 8.95 mmol/l 213 3.10  0.83 0.001 0.001 NS NS
IGT 104 2.99  0.81
Triglycerides (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 875 0.99  0.52
NGT with 1-h plasma glucose 8.95 mmol/l 220 1.28  0.88 0.001 0.001 NS 0.001
IGT 104 1.32  0.64
Data are means  SD unless otherwise indicated. n represents the absolute frequency and varies according to missing data for each variable. P values are reported
for statistical significance from ANOVA and Bonferroni post hoc comparisons.
Figure 1—Comparison of insulin sensitivity (A), -cell glucose sensitivity (B), rate sensitivity (C), potentiation factor (D), basal insulin secretion
(E), and total insulin secretion (F) among the following groups: NGT with 1-h plasma glucose 8.95 mmol/l (gray bars); NGT with 1-h plasma
glucose8.95 mmol/l (hatched bars), and IGT individuals (white bars). Significance is reported using the Bonferroni post hoc test.
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both obese youngsters (11,12) and adults
(3,13). However, these studies have fo-
cused on the association between dy-
namic parameters of -cell function and
2-h plasma glucose. Our study is unique
in that we have focused on 1-h plasma
glucose.
In clinical practice, neither IFG nor
IGT is considered a clinical entity but
rather both are risk categories for devel-
opment of type 2 diabetes and cardiovas-
cular disease. Glycemic thresholds are
based on a consensus interpretation of ev-
idence, with cutoff values representing
points at which risk is deemed excessive
(14,15). Nevertheless, studies have
shown that targeted treatment of IGT can
reduce progression to type 2 diabetes, and
the risk of cardiovascular disease or future
diabetes seems to be continuous across
the glucose range (16).
There are examples in the literature of
1-h plasma glucose being predictive of the
risk of myocardial infarction (17) and cor-
onary heart disease (18,19) in type 2 dia-
betes. One-hour plasma glucose was a
strong predictor of development of type 2
diabetes in a large cohort of 1,611 partic-
ipants without diabetes in the San Anto-
nio Heart Study (20,21). Furthermore,
1-h plasma glucose values improved the
accuracy of a model to predict develop-
ment of type 2 diabetes incorporating
components of the metabolic syndrome
(21), with a 1-h plasma glucose concen-
tration of 155 mg/dl (8.5 mmol/l) identi-
fied to stratify three classes of risk. In this
study 16.7% of participants with NGT
with 1-h plasma glucose concentration
155 mg/dl developed type 2 diabetes
over a 7- to 8-year period, whereas those
with NGT and 1-h plasma glucose 155
mg/l, plus the metabolic syndrome, were
at much higher risk for the development
of diabetes, exceeding that of those with
IGT (21). One-hour plasma glucose was
also shown to correlate more strongly
with surrogate measures of hepatic and
muscle insulin resistance and -cell dys-
function than 2-h plasma glucose (20).
Analysis of cohort data from the San An-
tonio Heart and the Botnia studies (22)
demonstrated that 1-h plasma glucose is a
better predictor of future type 2 diabetes
than 2-h plasma glucose with a 13.1-fold
increased OR for developing the disease
in subjects with higher 1-h plasma glu-
cose (155 mg/dl).
These observations are consistent
with the results of the present analysis,
supporting the concept that the 1-h
plasma glucose concentration can iden-
tify participants with NGT according to
current definitions who have an adverse
metabolic profile at an earlier stage. We
speculate that they too may benefit from
lifestyle (and possibly pharmacological)
interventions analogous to the state of
IGT (16).
A limitation of the present study is
lack of longitudinal data. However, such
data will be available through ongoing fol-
low-up of the RISC cohort. In contrast, a
major strength of our study is the consis-
tent methodology used to evaluate insulin
sensitivity across centers in a large Euro-
pean population.
In summary, our data suggest that 1-h
plasma glucose may represent an index of
metabolic impairment useful in clinical
practice to identify individuals with more
severe insulin resistance and impaired
-cell glucose sensitivity and rate sensi-
tivity. These individuals might benefit
from an intervention program (with diet,
exercise, and/or pharmacotherapy). Fu-
ture longitudinal studies are necessary to
evaluate the association between 1-h
plasma glucose and the risk of develop-
ment of type 2 diabetes and/or cardiovas-
cular disease.
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